Patents by Inventor Renate Margreiter

Renate Margreiter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SOLID-STATE FORMS OF 2-(3-(4-(1H-INDAZOL-5-YLAMINO)QUINAZOLIN-2-YL)PHENOXY)-N-ISOPROPYLACETAMIDE METHANE SULFONIC ACID SALT
    Publication number: 20240343712
    Abstract: The present invention relates to solid-state forms of 2-(3-(4-(1H-indazol-5-ylamino)quinazolin-2-yl)phenoxy)-N-isopropylacetamide methane sulfonic acid (INN: belumosudil mesylate) and processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising a solid-state form of the present invention and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prophylaxis of autoimmune diseases such as graft-versus-host disease (GvHD) and systemic sclerosis.
    Type: Application
    Filed: July 18, 2022
    Publication date: October 17, 2024
    Applicant: Sandoz AG
    Inventors: Hannes Lengauer, Renate Margreiter, Arthur Pichler
  • MANDELATE FORM OF 1-(4-(((6-AMINO-5-(4-PHENOXYPHENYL)PYRIMIDIN-4-YL)AMINO)METHYL)PIPERIDIN-1-YL)PROP-2-EN-1-ONE
    Publication number: 20240327379
    Abstract: The present invention relates to a mandelate form of 1-(4-(((6-amino-5-(4-phenoxyphenyl) pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one (INN: evobrutinib) and a process of producing the same. Furthermore, the invention relates to a pharmaceutical composition comprising the mandelate form of evobrutinib and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prevention of multiple sclerosis.
    Type: Application
    Filed: July 15, 2022
    Publication date: October 3, 2024
    Applicant: Sandoz AG
    Inventors: Hannes Lengauer, Renate Margreiter, Arthur Pichler
  • Crystalline Form of Sotorasib
    Publication number: 20240287066
    Abstract: The present invention relates to a crystalline form of sotorasib and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising the crystalline form of sotorasib of the present invention and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of a cancer with a KRAS mutation.
    Type: Application
    Filed: June 23, 2022
    Publication date: August 29, 2024
    Applicant: Sandoz AG
    Inventors: Verena Adamer, Renate Margreiter, Arthur Pichler
  • Co-crystal of an orally available HIF prolyl hydroxylase inhibitor
    Patent number: 11192860
    Abstract: The present invention relates to a co-crystal of roxadustat with L-proline and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said roxadustat L-proline co-crystal, at least one pharmaceutically acceptable excipient and optionally at least one photostabilizing agent. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prevention of anemia in patients with end-stage renal disease (ESRD) and/or chronic kidney disease (CKD).
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: December 7, 2021
    Inventors: Hannes Lengauer, Arthur Pichler, Renate Margreiter, Thomas Gelbrich
  • Co-Crystal of an Orally Available Hif Prolyl Hydroxylase Inhibitor
    Publication number: 20200262792
    Abstract: The present invention relates to a co-crystal of roxadustat with L-proline and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said roxadustat L-proline co-crystal, at least one pharmaceutically acceptable excipient and optionally at least one photostabilizing agent. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prevention of anemia in patients with end-stage renal disease (ESRD) and/or chronic kidney disease (CKD).
    Type: Application
    Filed: July 11, 2018
    Publication date: August 20, 2020
    Applicant: Sandoz AG
    Inventors: Hannes Lengauer, Arthur Pichler, Renate Margreiter, Thomas Gelbrich